A Case Study in Pharmacopoeia Compliance: Excipients and Raw Materials

News
Article

This case study is based on the experience of one of the authors but is applicable to all companies across the broader industry, illustrating the potentially surprising point that some compliance difficulties may be of the company’s own making.

External Link - PTebook0320_PharmacopeiaCompendia_Part11_ONLINE CaseStudy.pdf

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Ask the Expert: Adventitious Contamination Control
Ask the Expert: Adventitious Contamination Control
A CDMO’s Role in API Quality
A CDMO’s Role in API Quality
Ask the Expert: Quality Control Units
Ask the Expert: Quality Control Units
Industry Outlook 2025: European Geopolitical Impact on Pharma
Industry Outlook 2025: European Geopolitical Impact on Pharma
Industry Outlook 2025: Political Implications for Pharma
Industry Outlook 2025: Political Implications for Pharma
Ask the Expert: EU Data Protection
Ask the Expert: EU Data Protection
Industry Outlook 2025: The Impact of Politics on Pharma
Industry Outlook 2025: The Impact of Politics on Pharma
Industry Outlook 2025: Technology as a Supporting Element
Industry Outlook 2025: Technology as a Supporting Element
Industry Outlook 2025: Talent Up for Grabs
Industry Outlook 2025: Talent Up for Grabs
INTERPHEX 2025: ‘Breaking Up the Octopus’ of Single-Use Systems
INTERPHEX 2025: ‘Breaking Up the Octopus’ of Single-Use Systems
Related Content
Rueil-Malmaison, France - 13 août 2023: Siège social France de Bristol-Myers Squibb, entreprise pharmaceutique américaine née de la fusion entre Bristol-Myers Company et Squibb Corporation | Image Credit: © HJBC - stock.adobe.com

Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions

Patrick Lavery
July 22nd 2025
Article

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

EMA Moves to Secure Supply of Critical Drugs Used During Pregnancy

Susan Haigney
July 10th 2025
Article

The agency’s Executive Steering Group on Shortages and Safety of Medicinal Products has issued recommendations to address vulnerabilities in the supply chain of anti-D immunoglobulins.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Document Review and Quality Control Concept. Document with a checkmark, quality assurance, and process control. auditing, compliance, verification, data inspection, and business workflow management. | Image Credit: © Supatman - stock.adobe.com

A Novel, Enhanced, and Sustainable Approach to Audit Trail Review

Diana Russo
July 4th 2025
Article

Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Sandoz Recalls Cefazolin Due to Mispackaging, Opens Biosimilar Facility in Slovenia

Susan Haigney
July 2nd 2025
Article

The company is voluntarily recalling one lot of cefazolin for injection, USP, 1 gram per vial due to customer complaints of the wrong product being included in a carton.